Verification of imatinib cost-effectiveness in advanced gastrointestinal stromal tumor in British Columbia (VINCE-BC study)

Journal of Oncology Pharmacy Practice

Volumn 14, Issue 3, 2008, Pages 105-112

  Mabasa, Vincent H ^a   Taylor, Suzanne C M ^b   Chu, Christina C Y ^b   Moravan, Veronika ^b   Johnston, Karissa ^a,b   Peacock, Stuart ^a,b   Knowling, Meg ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Advanced gastrointestinal stromal tumors; Cost effectiveness; Health outcomes; Imatinib; Leiomyosarcomas; Population based research

Indexed keywords

IMATINIB; SUNITINIB; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ABDOMINAL BLEEDING; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANADA; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; COST BENEFIT ANALYSIS; DISEASE FREE SURVIVAL; ECONOMICS; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BRITISH COLUMBIA; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; LIFE EXPECTANCY; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; RETROSPECTIVE STUDIES;

EID: 58249092172     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078155208088695     Document Type: Article

References (24)

1. BC Cancer registry. GIST's and leiomyosarcomas of GI tract, 2001.
2. Miettinen M., Lasota J. Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438: 1-12.
3. Van Roggen JFG, Van Velthuysen MLF, Hogendoorn PCW. The histopathological differential diagnosis of gastrointestinal tumors. J Clin Pathol 2001; 54: 96-103.
4. Berman J., O'Leary TJ Perspectives in pathology: Gastrointestinal stromal tumor workshop. Hum Pathol 2001; 32: 578-82.
5. Plaat BEC, Hollema H., Molenaar WM et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: Differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 2000; 18: 3211-20.
6. Benjamin RS Should patients with advanced sarcomas be treated with chemotherapy? Eur J Cancer 1998; 34: 958-62.
7. Bedikian AY, Valdivieso M., Khankhanian N. et al. Chemotherapy for sarcoma of the stomach. Cancer Treat Rep 1979; 63: 411-14.
8. Edmonson JH, Marks RS, Buckner JC et al. Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest 2002; 20: 605-12.
9. Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: Before and after STI-571. Hum Pathol 2002; 33: 466-77.
10. Nilsson B., Bumming P., Meis-Kindblom JM et al. Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era. Cancer 2005; 103: 821-29.
11. Kitamura Y., Hayashi K. Pushing the imatinib envelope. Lancet 2004; 364: 1101-02.
12. Demetri GD, Von Mehren M., Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-80.
13. Joensuu H., Roberts P., Sarlomo-Rikala M. et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-56.
14. Van Oosterom AT, Judson IR, Verweij J. et al. Update of phase I study of imatinib (ST1571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: A report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002; 35 (Suppl 5): S83-87.
15. Benjamin RS, Rankin C., Fletcher C. et al. Phase III dose-randomized study of imatinib mesylate (STI571) for GIST: Intergroup S0033 early results. Proc Am Soc Clin Oncol 2003; 22: (abstract 3271).
16. Verweij J., Casali PG, Zalcberg J. et al. Early efficacy comparison of two doses of imatinib for the treatment of advanced gastro-intestinal stromal tumors (GIST): Interim results of a randomized phase III trial from the EORTC-STBSG, ISG and AGITG. Proc Am Soc Clin Oncol 2003; 22: (abstract 3272).
17. Blay JY, Bonvalot S., Casali P. et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST consensus conference of 20-21 march 2004, under the auspices of ESMO. Ann Oncol 2004; 16: 566-78.
18. Taylor SCM, Uyeno KT, O'Reilly SE et al. Development of a systemic therapy costing model in a provincial oncology centre (abstract). Eur J Cancer 2000; 36(Suppl 3): S26.
19. Taylor SCM, Chow L. Development of a pharmacoeconomics service in a provincial oncology program (abstract). Eur J Cancer 1997; 33 (Suppl 9): S31.
20. Greanya ED, Taylor SCM, Hu F. et al. Temozolamide for malignant gliomas in British Columbia: A population-based cost-effectiveness analysis. J Oncol Pharm Practice 2004; 10: 201-09.
21. Wilson J., Connock M., Song F. et al. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: Systematic review and economic evaluation. Health Technol Assess 2005; 9(25): 1-142.
22. Uyl-de Groot CA, Gianccone G. Health economics: Can we afford an unrestricted use of new biological agents in gastrointestinal oncology? Curr Opin Oncol 2005; 17: 392-96.
23. Gafni A., Birch S. Incremental cost-effectiveness ratios (ICERs): The silence of the lambda. Soc Sci Med 2006; 62: 2091-2100.
24. Verweij J., Casali PG, Zalcberg J. et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 2004; 364: 1127-34.